TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04499456

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalised Normative Feedback
Description: The Personalised Normative Feedback provides information on 1) alcohol consumption (the number of drinks consumed, alcohol-pattern use, binge drinking); 2) normative comparisons; 3) alcohol-related consequences; 4) practical costs of alcohol consumption (money spent and calories consumed); 5) strategies to avoid or risks associated with alcohol use.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Personalised Normative Feedback
Description: The Personalised Normative Feedback provides information on 1) alcohol consumption (the number of drinks consumed, alcohol-pattern use, binge drinking); 2) normative comparisons; 3) alcohol-related consequences; 4) practical costs of alcohol consumption (money spent and calories consumed); 5) strategies to avoid or risks associated with alcohol use.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalised Normative Feedback
Description: The Personalised Normative Feedback provides information on 1) alcohol consumption (the number of drinks consumed, alcohol-pattern use, binge drinking); 2) normative comparisons; 3) alcohol-related consequences; 4) practical costs of alcohol consumption (money spent and calories consumed); 5) strategies to avoid or risks associated with alcohol use.
Study: NCT01211574

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: peer coach
Description: Participants will receive behavioral weight loss treatment and be coached by a peer between treatment visits.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mentor
Description: Participants will receive behavioral weight loss treatment and be coached by a mentor between treatment visits.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Professional
Description: Participants will receive behavioral weight loss treatment and be coached by a behavioral weight loss interventionist between treatment visits.
Study: NCT02853929

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix hexa
Description: All subjects will receive Infanrix hexa co-administered with Prevenar13 as a booster dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa
Description: All subjects will receive Infanrix hexa co-administered with Prevenar13 as a booster dose.
Study: NCT00955747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tagatose
Description: powder; 15 grams three times daily; one year

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Substitute Splenda
Description: 1.5 g powder tid
Study: NCT03286647

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral hygiene instruction
Description: the participants will receive instructions to perform a satisfatory oral hygiene

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oral hygiene instruction
Description: the participants will receive instructions to perform a satisfatory oral hygiene

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral hygiene instruction
Description: the participants will receive instructions to perform a satisfatory oral hygiene
Study: NCT04465383

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aqua© 30 on Oncomfort SedakitTM
Description: Digital Sedation session consists in a virtual reality software (Aqua© 30 Version 3.0, Oncomfort SA, Waver, Belgium) including a clinical hypnosis script.Patients in the intervention group will undergo a 30-minute Digital Sedation program through a VR headset and headphones. This medical device called Oncomfort SedakitTM has been created to reduce anxiety and pain during medical/ surgical interventions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Standard sedation starting doses of 1 µg/ml to 6 µg/ml depending on patient's reaction and titrated incrementally by 0.5µg/ml. Doses are adapted according to the level of comfort and needs of the patient.
Study: NCT01554462

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Eicosapentaenoic acid / Docosahexaenoic acid
Description: 650 mg EPA and 650 mg DHA daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo dietary intervention (MUFA) in healthy control group
Description: Placebo contains MUFA in stead of PUFA, same energy value
Study: NCT04571905

Intervention type: DEVICE
Group type: OTHER
Intervention: Osteosynthesis with resorbable Material
Description: Osteosynthesis with Magnezix screws in fractures of the Epicondylus ulnaris and Condylus radialis under General anaesthesia
Study: NCT04471688

Intervention type: DIAGNOSTIC_TEST
Intervention: infectious disease screening
Description: Explore the best detection strategy for patients with pre-transfusion/pre-operative infectious disease screening
Study: NCT04465383

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Standard sedation starting doses of 1 µg/ml to 6 µg/ml depending on patient's reaction and titrated incrementally by 0.5µg/ml. Doses are adapted according to the level of comfort and needs of the patient.
Study: NCT03391297

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure Therapy
Description: PE consists of 10-15 treatment sessions. Treatment includes psychoeducation, in vivo exposure (i.e., confronting trauma-related situations and objects that are being avoided), imaginal exposure (i.e., revisiting and recounting traumatic memory) followed by processing (discussing the experience of revisiting the trauma memory, with a focus on new learning and changed beliefs or perspectives).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure Therapy
Description: PE consists of 10-15 treatment sessions. Treatment includes psychoeducation, in vivo exposure (i.e., confronting trauma-related situations and objects that are being avoided), imaginal exposure (i.e., revisiting and recounting traumatic memory) followed by processing (discussing the experience of revisiting the trauma memory, with a focus on new learning and changed beliefs or perspectives).
Study: NCT02308111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obeticholic Acid (OCA)
Description: Non-cirrhotic and classified as CP Class A: 5 mg tablet of OCA once daily titrating up to a maximum of 10 mg OCA once daily based on tolerability at 3 months for the duration of the study (majority of participants).~Cirrhotic and classified as CP Class B and C: 5 mg tablet of OCA once weekly for at least 3 months, subsequently titrating up to a maximum dose and frequency of 10 mg OCA twice weekly based on tolerability and biochemical response for the duration of the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tablet daily (or a lower frequency depending on CP score) for the remainder of the study
Study: NCT00012376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bryostatin 1
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given subcutaneously
Study: NCT04183790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELX/TEZ/IVA
Description: Fixed-dose combination (FDC) tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Mono tablet for oral administration.
Study: NCT03349606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: d-amphetamine
Description: oral d- amphetamine 0.5 mg/kg is used to stimulate dopamine release in the brain

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: d-amphetamine
Description: oral d- amphetamine 0.5 mg/kg is used to stimulate dopamine release in the brain

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [C-11]FLB 457
Description: PET radiotracer

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [C-11]FLB 457
Description: PET radiotracer
Study: NCT03419195

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiovascular exercise training
Description: Following the completion of baseline testing, both subject groups will undergo supervised cardiovascular exercise training 3 times per week for 3 months (plus a 3 week ramp-up). Exercise training will take place on a treadmill, stationary bicycle, elliptical, rowing machine, or combination of machines. Each session will last 1 hour, which includes a 5 minute warm-up, 50 minutes of exercise, and a 5 minute cool down.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiovascular exercise training
Description: Following the completion of baseline testing, both subject groups will undergo supervised cardiovascular exercise training 3 times per week for 3 months (plus a 3 week ramp-up). Exercise training will take place on a treadmill, stationary bicycle, elliptical, rowing machine, or combination of machines. Each session will last 1 hour, which includes a 5 minute warm-up, 50 minutes of exercise, and a 5 minute cool down.
Study: NCT01890707

Intervention type: PROCEDURE
Group type: OTHER
Intervention: General Anesthesia
Description: Administer: Fentanyl:1mcg/kg prior to induction, additional doses to maintain blood pressure and heart rate within 20% of preoperative values, Propofol:2mg/kg,succinylcholine, 0.5mg/kg,to be followed with Rocuronium if necessary,bolus: 0.4mg/kg, Sevoflurane and oxygen to be titrated to maintain BIS value of 40-60.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Sedation
Description: IV administration of Propofol,initial rate 100ug/kg/min, titrated to maintain BIS 65-75,Fentanyl,Ketamine,1mcg/kg,0.5mg/kg,additional 10mg increments for analgesia/movement.
Study: NCT02381509

Intervention type: DEVICE
Intervention: IVC Filter
Study: NCT01928914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine 300mg
Description: Single dose of Tafenoquine give on Day 3 only
Study: NCT00012376

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT01928914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine 600mg
Description: Single dose of Tafenoquine given on Day 3 only
Study: NCT04505930

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interventional HPV vaccination video modules
Description: The study team provide participants in the intervention group with interventional education, using interactive video watch and dynamic discussion. The educational videos were aiming to reinforcement and improvement the awareness, knowledge, attitude, intention and actual uptake of HPV vaccination shots among Chinese parents.
Study: NCT01928914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine 1200mg
Description: 400mg Dose of Tafenoquine given on each of the three consecutive dosing days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin
Description: moxifloxacine given on Day 3 only

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Tafenoquine
Description: Placebo given on all three days to all groups except for group 5 on Day 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Tafenoquine
Description: Placebo given on all three days to all groups except for group 5 on Day 3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Tafenoquine
Description: Placebo given on all three days to all groups except for group 5 on Day 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Tafenoquine
Description: Placebo given on all three days to all groups except for group 5 on Day 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Tafenoquine
Description: Placebo given on all three days to all groups except for group 5 on Day 3

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for moxifloxaxin
Description: Placebo for moxifloxacin, given to all groups on all days except for Group 3 on Day 3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for moxifloxaxin
Description: Placebo for moxifloxacin, given to all groups on all days except for Group 3 on Day 3
Study: NCT04505930

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Vaccination Education
Description: Education session conducted using only handouts of vaccinations including HPV
Study: NCT01928914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for moxifloxaxin
Description: Placebo for moxifloxacin, given to all groups on all days except for Group 3 on Day 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for moxifloxaxin
Description: Placebo for moxifloxacin, given to all groups on all days except for Group 3 on Day 3
Study: NCT02682290

Intervention type: OTHER
Group type: OTHER
Intervention: Expectoration and measurement of sputum rheological properties
Study: NCT01066481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-01913539 5 mg
Description: PF-01913539 5 mg three times daily for 6 months
Study: NCT02690818

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regularly scheduled LTBI medication reminder text messages
Description: Regularly scheduled medication reminder text messages Daily LTBI text messages without the option to text back. The messages will read, This is a reminder to take your medication.
Study: NCT01066481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-01913539 5 mg
Description: PF-01913539 5 mg three times daily for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo three times daily for 6 months
Study: NCT01987804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin 100 i.u.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin 400 i.u.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02542306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fibrinogen concentrate
Description: Investigators administered fibrinogen concentrate when the plasma fibrinogen level was below 1.5 g/L at 5 minutes after protamine reversal and completion of surgical hemostasis in patients, who comprised the fibrinogen concentrate-treated group.
Study: NCT00681863

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pramipexole 0.125 mg BID
Description: titrated dose for those patients whose symptoms were not controlled on the 0.0625 mg BID dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pramipexole 0.0625 mg QD
Description: dose down titrated for those patients unable to tolerate the 0.0625 mg BID dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pramipexole 0.125 mg TID
Description: titrated up for those patients whose symptoms were not adequately controlled on 0.125 mg BID dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pramipexole 0.25 mg BID
Description: titrated for those patients whose symptoms were not adequately controlled on 0.125 mg TID dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pramipexole 0.0625 mg BID
Description: 0.0625 mg BID given for first 4 wks of treatment
Study: NCT03150121

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uterine lavage
Description: Uterine lavage is performed using an intrauterine insemination catheter or rigid pipelle uterine sampler. The catheter is inserted into the cervical canal. 10mL of saline are infused into the uterine cavity and fallopian tubes and immediately retrieved.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Uterine lavage
Description: Uterine lavage is performed using an intrauterine insemination catheter or rigid pipelle uterine sampler. The catheter is inserted into the cervical canal. 10mL of saline are infused into the uterine cavity and fallopian tubes and immediately retrieved.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uterine lavage
Description: Uterine lavage is performed using an intrauterine insemination catheter or rigid pipelle uterine sampler. The catheter is inserted into the cervical canal. 10mL of saline are infused into the uterine cavity and fallopian tubes and immediately retrieved.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: 5-10mL of blood will be drawn from participants.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample
Description: 5-10mL of blood will be drawn from participants.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: 5-10mL of blood will be drawn from participants.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Uterine lavage catheter
Description: Uterine lavage is performed using an intrauterine insemination catheter or rigid pipelle uterine sampler. The catheter is inserted into the cervical canal. 10mL of saline are infused into the uterine cavity and fallopian tubes and immediately retrieved.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Uterine lavage catheter
Description: Uterine lavage is performed using an intrauterine insemination catheter or rigid pipelle uterine sampler. The catheter is inserted into the cervical canal. 10mL of saline are infused into the uterine cavity and fallopian tubes and immediately retrieved.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Uterine lavage catheter
Description: Uterine lavage is performed using an intrauterine insemination catheter or rigid pipelle uterine sampler. The catheter is inserted into the cervical canal. 10mL of saline are infused into the uterine cavity and fallopian tubes and immediately retrieved.
Study: NCT03131999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate 400Mg Capsule
Description: Sirolimus or everolimus will be withdrawn after 28 days if used at baseline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Capsule
Description: Sirolimus or everolimus will be withdrawn after 28 days if used at baseline
Study: NCT05044442

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: moderate intensity continous training
Description: Participants will complete 6 sessions of moderate intensity continous training during a 2 week intervention period. Participants will be asked to complete 30 minutes of continuous exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high intensity interval training
Description: Participants will complete 6 sessions of high intensity interval training during a 2 week intervention period. The programme involves repeated 1 minute bouts of simple on the spot movements interspersed with 1 minute of rest.
Study: NCT01323998

Intervention type: DRUG
Intervention: 5ARI
Description: Dutasteride or Finasteride

Intervention type: DRUG
Intervention: 5ARI
Description: Dutasteride or Finasteride
Study: NCT00874627

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Milk
Description: sublingual administration of milk
Study: NCT01323998

Intervention type: DRUG
Intervention: 5ARI
Description: Dutasteride or Finasteride

Intervention type: DRUG
Intervention: AB
Description: Doxazosin, Prazosin, Tamsulosin, Terazosin or Alfuzosin

Intervention type: DRUG
Intervention: AB
Description: Doxazosin, Prazosin, Tamsulosin, Terazosin or Alfuzosin

Intervention type: DRUG
Intervention: AB
Description: Doxazosin, Prazosin, Tamsulosin, Terazosin or Alfuzosin
Study: NCT01844934

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: The three week, 3 days / week prehabilitation exercise program will consist of resistance training, step training and stretching(flexibility) as well as cardiovascular endurance training. Intensity of training will increase over the three weeks. Classes will be delivered over a four week period with a gap during the third week allowing additional time for participants to practice their exercises. The home exercise program will be designed to account for the additional week.
Study: NCT03239275

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biocreative therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biocreative therapy
Study: NCT00599183

Intervention type: OTHER
Group type: OTHER
Intervention: MRI-Diffusion Tensor Imaging and Tractrography
Description: MRI scan: Baseline: Conventional MRI (as part of clinical care) with additional diffusion tensor imaging (DTI)sequence (research). 6-week follow up: MRI with DTI and tractography as part of the research
Study: NCT04110977

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mobile application (reminder app)
Description: This app will remind the patients four times a day to perform skin and mouth care. Instructions are given how to properly perform skin and mouth care. The patients may postpone each required care procedure for up to 2 hours. Finally, the patients are asked to state for each procedure whether or not they performed it. To increase the patients' motivation, they will earn points for each successfully performed care procedure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mobile application (reminder app)
Description: This app will remind the patients four times a day to perform skin and mouth care. Instructions are given how to properly perform skin and mouth care. The patients may postpone each required care procedure for up to 2 hours. Finally, the patients are asked to state for each procedure whether or not they performed it. To increase the patients' motivation, they will earn points for each successfully performed care procedure.